NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Sell
44
PHVS Quote, Financials, Valuation and Earnings
Last price:
$19.46
Seasonality move
:
3.9%
Day range:
$18.77 - $20.48
52-week range:
$15.37 - $33.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.27x
Volume:
97.1K
Avg. volume:
85.3K
1-year change:
-24.59%
Market cap:
$1.1B
Revenue:
--
EPS (TTM):
-$2.82
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PHVS
Pharvaris NV
|
-- | -$0.66 | -- | -6.9% | -- |
|
ARGX
argenx SE
|
$539.9M | $0.06 | 62.39% | -44.75% | $655.15 |
|
MRUS
Merus NV
|
$8.7M | -$0.85 | -4.27% | -10.77% | $86.07 |
|
PHAR
Pharming Group
|
$76M | -$0.00 | 0.91% | -- | -- |
|
PRQR
ProQR Therapeutics NV
|
$12.3M | -$0.14 | 25.16% | -54.98% | $4.10 |
|
QURE
uniQure NV
|
$7.1M | -$1.01 | 194.09% | -62.87% | $30.72 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PHVS
Pharvaris NV
|
$19.99 | -- | $1.1B | -- | $0.00 | 0% | -- |
|
ARGX
argenx SE
|
$623.82 | $655.15 | $37.3B | -- | $0.00 | 0% | 20.45x |
|
MRUS
Merus NV
|
$41.87 | $86.07 | $2.9B | -- | $0.00 | 0% | 71.67x |
|
PHAR
Pharming Group
|
$9.10 | -- | $617.3M | -- | $0.00 | 0% | 2.36x |
|
PRQR
ProQR Therapeutics NV
|
$2.66 | $4.10 | $281.2M | -- | $0.00 | 0% | 11.17x |
|
QURE
uniQure NV
|
$16.98 | $30.72 | $827.7M | -- | $0.00 | 0% | 28.74x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PHVS
Pharvaris NV
|
-- | -2.127 | -- | -- |
|
ARGX
argenx SE
|
-- | -0.253 | -- | 7.52x |
|
MRUS
Merus NV
|
-- | 1.520 | -- | 7.94x |
|
PHAR
Pharming Group
|
29.71% | -1.043 | 17.05% | 2.76x |
|
PRQR
ProQR Therapeutics NV
|
15.29% | -1.974 | 3.39% | 2.29x |
|
QURE
uniQure NV
|
47.8% | 0.153 | 21.27% | 6.18x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PHVS
Pharvaris NV
|
-- | -$41.7M | -- | -- | -- | -$38.1M |
|
ARGX
argenx SE
|
$514.2M | $16.2M | -5.47% | -6.01% | 15.47% | -$147M |
|
MRUS
Merus NV
|
-- | -$72.2M | -47.97% | -47.97% | -613.59% | -$80.7M |
|
PHAR
Pharming Group
|
$68M | $4.1M | -5.33% | -8.24% | 6.03% | $9.4M |
|
PRQR
ProQR Therapeutics NV
|
-- | -$9.7M | -59.09% | -66.59% | -230.39% | -$7.1M |
|
QURE
uniQure NV
|
$1.3M | -$40.2M | -96.96% | -154.29% | -1215.48% | -$45.3M |
Pharvaris NV vs. Competitors
-
Which has Higher Returns PHVS or ARGX?
argenx SE has a net margin of -- compared to Pharvaris NV's net margin of 15.95%. Pharvaris NV's return on equity of -- beat argenx SE's return on equity of -6.01%.
Company Gross Margin Earnings Per Share Invested Capital PHVSPharvaris NV-- -$0.85 -- ARGXargenx SE89.7% $1.39 $4.3B -
What do Analysts Say About PHVS or ARGX?
Pharvaris NV has a consensus price target of --, signalling upside risk potential of 72.95%. On the other hand argenx SE has an analysts' consensus of $655.15 which suggests that it could grow by 5.02%. Given that Pharvaris NV has higher upside potential than argenx SE, analysts believe Pharvaris NV is more attractive than argenx SE.
Company Buy Ratings Hold Ratings Sell Ratings PHVSPharvaris NV0 0 0 ARGXargenx SE13 2 0 -
Is PHVS or ARGX More Risky?
Pharvaris NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison argenx SE has a beta of 0.589, suggesting its less volatile than the S&P 500 by 41.058%.
-
Which is a Better Dividend Stock PHVS or ARGX?
Pharvaris NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. argenx SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharvaris NV pays -- of its earnings as a dividend. argenx SE pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHVS or ARGX?
Pharvaris NV quarterly revenues are --, which are smaller than argenx SE quarterly revenues of $573.2M. Pharvaris NV's net income of -$45.9M is lower than argenx SE's net income of $91.4M. Notably, Pharvaris NV's price-to-earnings ratio is -- while argenx SE's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharvaris NV is -- versus 20.45x for argenx SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHVSPharvaris NV-- -- -- -$45.9M ARGXargenx SE20.45x -- $573.2M $91.4M
-
Which has Higher Returns PHVS or MRUS?
Merus NV has a net margin of -- compared to Pharvaris NV's net margin of -848.67%. Pharvaris NV's return on equity of -- beat Merus NV's return on equity of -47.97%.
Company Gross Margin Earnings Per Share Invested Capital PHVSPharvaris NV-- -$0.85 -- MRUSMerus NV-- -$1.46 $703.3M -
What do Analysts Say About PHVS or MRUS?
Pharvaris NV has a consensus price target of --, signalling upside risk potential of 72.95%. On the other hand Merus NV has an analysts' consensus of $86.07 which suggests that it could grow by 105.57%. Given that Merus NV has higher upside potential than Pharvaris NV, analysts believe Merus NV is more attractive than Pharvaris NV.
Company Buy Ratings Hold Ratings Sell Ratings PHVSPharvaris NV0 0 0 MRUSMerus NV12 0 0 -
Is PHVS or MRUS More Risky?
Pharvaris NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Merus NV has a beta of 1.071, suggesting its more volatile than the S&P 500 by 7.125%.
-
Which is a Better Dividend Stock PHVS or MRUS?
Pharvaris NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merus NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharvaris NV pays -- of its earnings as a dividend. Merus NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHVS or MRUS?
Pharvaris NV quarterly revenues are --, which are smaller than Merus NV quarterly revenues of $11.8M. Pharvaris NV's net income of -$45.9M is higher than Merus NV's net income of -$99.9M. Notably, Pharvaris NV's price-to-earnings ratio is -- while Merus NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharvaris NV is -- versus 71.67x for Merus NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHVSPharvaris NV-- -- -- -$45.9M MRUSMerus NV71.67x -- $11.8M -$99.9M
-
Which has Higher Returns PHVS or PHAR?
Pharming Group has a net margin of -- compared to Pharvaris NV's net margin of -1.38%. Pharvaris NV's return on equity of -- beat Pharming Group's return on equity of -8.24%.
Company Gross Margin Earnings Per Share Invested Capital PHVSPharvaris NV-- -$0.85 -- PHARPharming Group90.89% -$0.02 $321.2M -
What do Analysts Say About PHVS or PHAR?
Pharvaris NV has a consensus price target of --, signalling upside risk potential of 72.95%. On the other hand Pharming Group has an analysts' consensus of -- which suggests that it could grow by 196.7%. Given that Pharming Group has higher upside potential than Pharvaris NV, analysts believe Pharming Group is more attractive than Pharvaris NV.
Company Buy Ratings Hold Ratings Sell Ratings PHVSPharvaris NV0 0 0 PHARPharming Group0 0 0 -
Is PHVS or PHAR More Risky?
Pharvaris NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pharming Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PHVS or PHAR?
Pharvaris NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharming Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharvaris NV pays -- of its earnings as a dividend. Pharming Group pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHVS or PHAR?
Pharvaris NV quarterly revenues are --, which are smaller than Pharming Group quarterly revenues of $74.8M. Pharvaris NV's net income of -$45.9M is lower than Pharming Group's net income of -$1M. Notably, Pharvaris NV's price-to-earnings ratio is -- while Pharming Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharvaris NV is -- versus 2.36x for Pharming Group. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHVSPharvaris NV-- -- -- -$45.9M PHARPharming Group2.36x -- $74.8M -$1M
-
Which has Higher Returns PHVS or PRQR?
ProQR Therapeutics NV has a net margin of -- compared to Pharvaris NV's net margin of -210.98%. Pharvaris NV's return on equity of -- beat ProQR Therapeutics NV's return on equity of -66.59%.
Company Gross Margin Earnings Per Share Invested Capital PHVSPharvaris NV-- -$0.85 -- PRQRProQR Therapeutics NV-- -$0.11 $32.9M -
What do Analysts Say About PHVS or PRQR?
Pharvaris NV has a consensus price target of --, signalling upside risk potential of 72.95%. On the other hand ProQR Therapeutics NV has an analysts' consensus of $4.10 which suggests that it could grow by 201.32%. Given that ProQR Therapeutics NV has higher upside potential than Pharvaris NV, analysts believe ProQR Therapeutics NV is more attractive than Pharvaris NV.
Company Buy Ratings Hold Ratings Sell Ratings PHVSPharvaris NV0 0 0 PRQRProQR Therapeutics NV2 1 0 -
Is PHVS or PRQR More Risky?
Pharvaris NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ProQR Therapeutics NV has a beta of 0.240, suggesting its less volatile than the S&P 500 by 75.965%.
-
Which is a Better Dividend Stock PHVS or PRQR?
Pharvaris NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProQR Therapeutics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharvaris NV pays -- of its earnings as a dividend. ProQR Therapeutics NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHVS or PRQR?
Pharvaris NV quarterly revenues are --, which are smaller than ProQR Therapeutics NV quarterly revenues of $4.2M. Pharvaris NV's net income of -$45.9M is lower than ProQR Therapeutics NV's net income of -$8.9M. Notably, Pharvaris NV's price-to-earnings ratio is -- while ProQR Therapeutics NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharvaris NV is -- versus 11.17x for ProQR Therapeutics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHVSPharvaris NV-- -- -- -$45.9M PRQRProQR Therapeutics NV11.17x -- $4.2M -$8.9M
-
Which has Higher Returns PHVS or QURE?
uniQure NV has a net margin of -- compared to Pharvaris NV's net margin of -1940.45%. Pharvaris NV's return on equity of -- beat uniQure NV's return on equity of -154.29%.
Company Gross Margin Earnings Per Share Invested Capital PHVSPharvaris NV-- -$0.85 -- QUREuniQure NV55.36% -$0.91 $106.9M -
What do Analysts Say About PHVS or QURE?
Pharvaris NV has a consensus price target of --, signalling upside risk potential of 72.95%. On the other hand uniQure NV has an analysts' consensus of $30.72 which suggests that it could grow by 80.94%. Given that uniQure NV has higher upside potential than Pharvaris NV, analysts believe uniQure NV is more attractive than Pharvaris NV.
Company Buy Ratings Hold Ratings Sell Ratings PHVSPharvaris NV0 0 0 QUREuniQure NV8 2 0 -
Is PHVS or QURE More Risky?
Pharvaris NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison uniQure NV has a beta of 0.895, suggesting its less volatile than the S&P 500 by 10.539%.
-
Which is a Better Dividend Stock PHVS or QURE?
Pharvaris NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. uniQure NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharvaris NV pays -- of its earnings as a dividend. uniQure NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHVS or QURE?
Pharvaris NV quarterly revenues are --, which are smaller than uniQure NV quarterly revenues of $2.3M. Pharvaris NV's net income of -$45.9M is lower than uniQure NV's net income of -$44.4M. Notably, Pharvaris NV's price-to-earnings ratio is -- while uniQure NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharvaris NV is -- versus 28.74x for uniQure NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHVSPharvaris NV-- -- -- -$45.9M QUREuniQure NV28.74x -- $2.3M -$44.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is up 2.15% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 12.5% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 5.85% over the past day.
